Most chronic metabolic diseases, such as diabetes, non-alcoholic steatohepatitis and growth hormone deficiency, are linked to metabolic disorders in human. These diseases can be caused by a variety of factors, including genetic inheritance, external environment, and personal habits. However, due to the complex nature of metabolic diseases and the significant individual differences among patients, it is difficult to determine the exact pathogenic mechanism. As a result, there are many candidate drug targets for each specific indication.

Drugs for metabolic diseases mainly include small molecule chemicals, polypeptides and proteins. Among them, polypeptides and proteins are mainly hormone agonists. For example, diabetic patients can regulate their blood glucose levels by injecting or orally taking polypeptide drugs such as insulin and GLP-1; injecting recombinant growth hormone can alleviate the symptoms of growth hormone deficiency.

As genetic engineering and solid phase chemical synthesis technology continue to advance, and fundamental research information is constantly updated, the applications of polypeptide drugs are expanding. For example, GLP-1 analogs, such as Semaglutide and Tirzepatide, are continuously being developed, leading to the optimization of efficacy and safety data in the antidiabetic field. Furthermore, the applications of these polypeptide analogs have been expanded to areas such as weight loss and prevention of cardiovascular disease. This highlights the wide range of potential applications for metabolic polypeptide agonists drugs.

Based on the earlier advantage in recombinant protein technology and independent research and development of tool enzyme system accumulated by Bovax technical team, Bovax has conducted extensive research in recombinant polypeptide and recombinant protein agonist drugs in the past decade. Currently, the product pipelines include antidiabetic drugs, lipid-decreasing drugs, growth hormone deficiency drugs, non-alcoholic steatohepatitis drugs, and anti-aging drugs. Among them, Insulin Degludec and Semaglutide are in Phase III clinical stage. Bovax is actively exploring new polypeptide and protein hormone projects in various areas, with a focus on developing new polypeptide analogs and long-acting formulations, it aims to become a leading team in the domestic market for recombinant metabolic hormone drugs.